PBYI

Puma Biotechnology, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:48 UTC

Last close

10.69USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-26

13.3xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
25.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
The filing itself
13.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
18.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
0.22Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.32 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one dollar

lens 1 of 9

After what it costs to make

74.5%

After running the business

16.3%

After interest and tax

13.6%

After what it must reinvest

18.3%

Kept after the dividend

n/a

after what it costs to make, 74.5% of sales; after running the business, 16.3% of sales; after interest and tax, 13.6% of sales; after what it must reinvest, 18.3% of sales

The five stops

4 of 5 read

After what it costs to make170,214,00074.5%
After running the business37,299,00016.3%
After interest and tax31,111,00013.6%
After what it must reinvest41,731,00018.3%
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales228,371,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
After what it costs to make170,214,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
After running the business37,299,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
After interest and tax31,111,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
After what it must reinvest41,731,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself
Kept after the dividendn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-005891
Reported in
USD
The filing itself